

#5/B
7-2-00
M.L.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on 3/16/00
TOWNSEND and TOWNSEND and CREW LLP
By: [Signature]

PATENT
Attorney Docket No.: 17634-000330US
Client Reference No.: E-089-97/5



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brian R. Murphy et al.

Application No.: 09/458,813

Filed: December 10, 1999

For: USE OF RECOMBINANT LIVE-ATTENUATED PARAINFLUENZA VIRUS (PIV) AS A VECTOR TO PROTECT AGAINST DISEASE CAUSED BY PIV AND RESPIRATORY SYNCYTIAL VIRUS (RSV)

Art Unit: Unassigned

Examiner: Unassigned

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

IN THE CLAIMS:

Please amend claims 1, 21, 22, 39, 48 and 50, as follows:

B1
cont.

- 1 1. (Amended) An isolated infectious chimeric parainfluenza virus (PIV)
- 2 comprising a major nucleocapsid (N) protein, a nucleocapsid phosphoprotein (P), a large
- 3 polymerase protein (L), and a partial or complete human parainfluenza virus 3 JS (HPIV3 JS)
- 4 vector genome or antigenome that incorporates at least one and up to a full complement of
- 5 attenuating mutations present within HPIV3 JS cp45 selected from mutations specifying an
- 6 amino acid substitution in the L protein at a position corresponding to Tyr₉₄₂, Leu₉₉₂, or Thr₁₅₅₈
- 7 of JS cp45; in the N protein at a position corresponding to residues Val₉₆ or Ser₃₈₉ of JS cp45,
- 8 in the C protein at a position corresponding to Ile₉₆ of JS cp45, a nucleotide substitution in a 3'